Technology & Marketing Law Blog

OCTOBER 6, 2023

He claims that third party “contributors” uploaded his copyrighted photos to ShutterStock as part of ShutterStock’s licensing program. Specifically, McGucken claims that a total of 337 images were uploaded, of which 165 were downloaded and that led to 938 licenses. TL;DR: “see Steinmetz.” Case Citation : McGucken v.

Licensing 79

Licensing Blogging Settlement Litigation 79

LexBlog IP

JANUARY 25, 2024

As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023. Below are some of the top regulatory developments from 2023. Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023.

Marketing 52

Marketing Marketing Licensing Litigation 52

Intellectual Property Law Blog

NOVEMBER 7, 2023

To prove damages at trial, Cyntec presented a market-share lost profits theory, alleging that 27 companies purchased Chilisin’s accused chokes outside the United States and then imported devices including the chokes into the United States. Similarly, in the second case, Niazi Licensing Corporation v. Jude Medical S.C.,

Art 260

Art Licensing Marketing Marketing 260

Kluwer Copyright Blog

JANUARY 4, 2024

Welcome to the fourth (and last) round up of EU copyright law for 2023! With Bulgaria implementing the directive towards the end of 2023, Poland is the last Member State missing. Photo by Markus Spiske on Unsplash Dear readers, Happy new year! The end of the year was busy for both the courts and the policy makers.

Copyright Law 73

Copyright Law Law Copyright Reporting 73

LexBlog IP

MARCH 6, 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. entry date for its ustekinumab biosimilar, WEZLANA, of January 1, 2025, and in October 2023, the FDA approved WEZLANA as biosimilar to and interchangeable with STELARA. Amgen secured a U.S.

Marketing 52

Marketing Marketing Settlement Licensing 52

Copyright Lately

NOVEMBER 8, 2022

A new crop of copyrighted works (including rights in a certain famous British detective) will enter the public domain in the United States on January 1, 2023. public domain on January 1, 2023. Happy Public Domain Day 2023. On January 1, 2023, Frank and Joe Hardy will be in good company. public domain on January 1, 2023.

Public Domain 145

Public Domain Derivative Work Copyright Social Media 145

The IPKat

JULY 7, 2023

The 2023 “analog” conference on the Metaverse took place in London, lasted three days and hosted several panels and addresses on the different aspects of the IP legal regime concerning the Metaverse and the possibilities of regulation of this changing environment.

Reporting 86

Reporting Music IP Intellectual Property 86

SpicyIP

OCTOBER 31, 2023

Image from here Recently, the Print reported that Novartis and Eli Lilly have voiced their opposition to the idea of compulsory licensing (“ CL ”) for breast cancer medications, Ribociclib and Abemaciclib. 98,374 in 2023 , making drug contributions excessive. It also says that no licenses were given out. of GDP in FY23.

Licensing 72

Licensing Government Reporting Patent 72

LexBlog IP

JUNE 30, 2023

On June 29 and 30, 2023, respectively, Formycon AG (“Formycon”) and Celltrion Inc. (“Celltrion”) announced submission to the FDA of aBLAs for their aflibercept biosimilar candidates. ’s submission in October 2021. As we have previously reported , Biocon Biologics Ltd.

Marketing 40

Marketing Marketing Reporting Licensing 40

LexBlog IP

JANUARY 19, 2024

As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market. The following is a recap of some of the top five legal decisions and developments in the biosimilars and biologics space in 2023 that we covered on the Big Molecule Watch.

Settlement 52

Settlement Litigation Patent Reporting 52

The IPKat

AUGUST 16, 2021

Over to Konstantin for the story and his take on the developments: "Some may associate businesses whose primary aim is to assert patents in litigation to obtain license revenue with the Eastern District of Texas or the Unwired Planet decision in the UK, and not think about cases further afield from Marshall, Texas or London. Cue our story.

Patent Troll 86

Patent Troll Marketing Marketing Patent 86

TorrentFreak

MAY 13, 2023

The major threat in today’s market has been growing for many years, mainly because it’s so quick and easy. The fact that the music industry has made virtually all of its content available at a fair price (or free) means that the ripping phenomenon cannot be attributed to the labels failing to read the market.

Music 133

Music Branding Brands Branding 133

LexBlog IP

DECEMBER 30, 2021

biosimilar market developments of 2021. market, as each biosimilar applicant has entered into a license agreement with AbbVie that permits the applicant to begin U.S. marketing only after a specified date in 2023. CYLTEZO is not scheduled to launch until July 1, 2023, pursuant to a settlement agreement with AbbVie.

Marketing 52

Marketing Marketing Settlement Licensing 52

SpicyIP

SEPTEMBER 27, 2023

At a quick glance, one notable push by the guidelines is to allow “exclusive” licensing from public funded research, to private bodies. d also mentions ‘march-in’ rights and compulsory licensing but the language makes it unclear what is meant exactly: 5.d. DPIIT Observations 01st February, 2023 10.

Intellectual Property 111

Intellectual Property Licensing IP Reporting 111

LexBlog IP

MAY 19, 2023

In 1984, Vanity Fair sought to license the photograph for an “artist reference” in a story about the musician. Goldsmith agreed to license a one-time use of the photograph with full attribution. AWF licensed the “Orange Prince” to Condé Nast for an article about Prince.

Licensing 52

Licensing Fair Use Copyright Derivative Work 52

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

Patently-O

SEPTEMBER 28, 2023

The new deadline is November 6, 2023. On September 11, 2023, the three agencies jointly published a request for comments in the Federal Register seeking input from stakeholders on issues related to standards and intellectual property, especially as they impact small and medium enterprises in critical and emerging technologies.

Intellectual Property 67

Intellectual Property Licensing Technology Publishing 67

IP Watchdog

OCTOBER 24, 2023

On April 27, 2023, the European Commission published its proposal for how the licensing of standard essential patents (SEPs) should be governed in the EU. The developments are of interest to any business that develops, implements or markets connective technologies.

Licensing 52

Licensing Government Technology Publishing 52

The IPKat

AUGUST 22, 2023

IP Essentials for Start Ups and SMEs – 11th October 2023 The free webinar analyses the functional basis of the key intellectual property rights linked to Start-Ups and SMEs, in order to help these businesses develop an IP strategy aimed at innovation and at delivering new products and services to the market. More details here.

Intellectual Property 52

Intellectual Property Confidentiality IP Licensing 52

The IPKat

MARCH 21, 2024

The reversal of the first instance decision by the UPC CoA in UPC_CoA_335/2023 puts pay to some of these initial hopes/criticisms. At first instance before the Munich Local Division of the UPC, 10x Genomics requested a preliminary injunction against NanoString (UPC CFI 2/2023, IPKat ).

Invention 57

Invention Art Patent Licensing 57

JD Supra Law

JULY 21, 2023

On June 30, 2023, China’s antitrust authority – the State Administration for Market Regulation (SAMR) – released draft guideline on standard essential patents (SEPs) for public comment. The comment period ends on July 29, 2023.

Licensing 52

Licensing Marketing Marketing Patent 52

SpicyIP

SEPTEMBER 25, 2023

Notably, in July 2021, a breast cancer patient petitioned the Kerala High Court , urging the government to issue a compulsory license for the production of a generic version of Ribociclib, a drug developed and marketed by Novartis, as well as Abemaciclib, a product of Eli Lilly.

Patent 104

Patent Intellectual Property Licensing Registration 104

Technology & Marketing Law Blog

AUGUST 12, 2023

Also, the CRFA declares gag contracts to be “unlawful,” and I wonder if Hah’s commission of an “unlawful” act could impact his medical license. Not only does it exacerbate the Streisand Effect, but it risks malpractice counterclaims and complaints to the licensing board. Hah , 2023 WL 5122528 (Tex.

Contracts 69

Contracts Licensing Business Blogging 69

Velocity of Content

OCTOBER 9, 2023

On Thursday, October 12, 2023, 1000 EDT/1500 BST/1600 CEST, CCC presents a Town Hall special program on LinkedIn Live, “AI, Licensing & The Path Forward.” As a legal precedent, Texaco paved the way for far broader license acceptance by Fortune 100 and other corporations,” he noted.

Licensing 52

Licensing Fair Use Journalism Copyright Law 52

SpicyIP

OCTOBER 7, 2023

We recently came across one such short paper on “ SEP Litigations & Issues in Determining the FRAND License ” published in the September 2023 issue of the Journal of Intellectual Property Rights (see here ) and extended a guest post invitation to its authors to discuss their key arguments. Apple Retail UK Ltd.

Licensing 105

Licensing Litigation Technology Patent 105

IIPRD

JANUARY 18, 2024

In contrast to this, the Competition Law aims to prevent monopoly and provide fair competition and aims at reducing entry barriers in the market. For example, in the case of a Patent, the exclusive power to grant a license to the Patented product lies only with the Patentee. Competition Commission of India, 2023.

Intellectual Property Law 52

Intellectual Property Law Intellectual Property Law Licensing 52

The IP Law Blog

MARCH 30, 2023

Most of these fee reductions have an effective date of March 22, 2023, with the remaining ones effective as of April 1, 2023. For example, they can increase the value of a business, provide an advantage over competitors, and serve as a source of income through licensing. A small entity is defined under 37 CFR § 1.27

Business 98

Business Inventor Patent Licensing 98

Plagiarism Today

AUGUST 1, 2022

However, those big ideas ran into significant issues, most importantly copyright and the collapse of much of the cryptocurrency market. The 3 Count Logo was created by Justin Goff and is licensed under a Creative Commons Attribution License. The post 3 Count: Bright House Begins appeared first on Plagiarism Today.

Copying 176

Copying Publishing Plagiarism Reporting 176

LexBlog IP

MARCH 5, 2024

The approval follows Alvotech’s successful resubmission of a Biologics License Application announced on September 20, 2023 for the monoclonal antibody AVT02. Prior to FDA’s approval, AVT02 had already been on the market in various other countries.

Marketing 52

Marketing Marketing Licensing Reporting 52

TorrentFreak

DECEMBER 15, 2023

Does 1-10 are described as the infringing IPTV service’s operators, who knowingly and unlawfully transmit, and publicly perform in the United States, TV channels for which DISH holds or held an exclusive license. “Rays markets and brands the Infringing Service as, alternatively, Glo TV, Rays IPTV, and Rays TV.

Cease and Desist 83

Cease and Desist Copyright Infringement Branding Brands 83

LexBlog IP

NOVEMBER 16, 2023

Earlier today, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for their CRISPR/Cas9 gene therapy, CASGEVY (exagamglogene autotemcel), marking the world’s first regulatory approval for a CRISPR-based gene-edited therapy.

Editing 52

Editing Licensing Reporting Marketing 52

43(B)log

OCTOBER 27, 2023

Under the European Union’s new Article 17, sites like YouTube are now required to negotiate with copyright owners to license works uploaded by users who do not own the copyright thereto. Marketing Sci., Marketing Sci., YouTube, however, was already doing this. RT: This was kind of frustrating!

Music 59

Music Licensing Copyright Marketing 59

JD Supra Law

MARCH 21, 2022

settlement agreement with Abbvie that grants Alvotech non-exclusive rights to market AVT02 (adalimumab) in the U.S starting July 1, 2023. AbbVie confirmed the resolution of disputes and stated that Alvotech will take a non-exclusive license to the patents, and in return, pay royalties and acknowledge the licensed patents’ validity.

Settlement 52

Settlement Licensing Marketing Marketing 52

LexBlog IP

NOVEMBER 9, 2023

As previously reported , in February 2023, Formycon and Fresenius Kabi entered into a global license agreement to commercialize FYB202, a ustekinumab biosimilar of Janssen’s STELARA, in key global markets after successful regulatory approvals.

Reporting 52

Reporting Marketing Marketing Licensing 52

Plagiarism Today

AUGUST 2, 2022

Spice DAO has announced that it is implementing a three-stage “redemption phase” that will see it attempt to pay back its members as much as possible and, likely, attempt to sell the book in the fourth quarter of 2023. For example, blockchain could be used to record that someone obtained a license to use a song in a video.

Copyright 243

Copyright Non-Fungible Tokens Technology Plagiarism 243

Technology & Marketing Law Blog

AUGUST 19, 2023

2023 WL 5318464 (9th Cir. August 18, 2023) The post Ninth Circuit Easily Dismisses Account Termination Case–King v. Facebook appeared first on Technology & Marketing Law Blog. Case citation : Adrienne Sepaniak King and Christopher Edward Sepaniak King v. Facebook, Inc.

Blogging 85

Blogging Publishing Marketing Marketing 85

LexBlog IP

JANUARY 12, 2023

The parties expect to complete the transaction in Q1 2023. Coherus plans to file an abbreviated Biologics License Application (aBLA) with the FDA later this year and intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025.

Marketing 52

Marketing Marketing Licensing Intellectual Property 52